459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither [PDF]
, 2021 R. Scott Wright +7 more
openalex +1 more source
New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran [PDF]
, 2021 Massimiliano Ruscica +3 more
openalex +1 more source
Inclisiran: A New Pharmacological Approach for Hypercholesterolemia [PDF]
, 2022 Stefania Angela Di Fusco +12 more
openalex +1 more source
PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection [PDF]
, 2022 Natalie Arnold, Wolfgang Köenig
openalex +1 more source
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials [PDF]
, 2022 Wolfgang Köenig +8 more
openalex +1 more source
New technology in the hypolipidemic drugs development. Inclisiran (LEQVIO) [PDF]
, 2022 Hana Rosolová
openalex +1 more source
Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia [PDF]
, 2023 Oluwakemi Ebenezer +3 more
openalex +1 more source
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol [PDF]
, 2020 Kausik K. Ray +10 more
openalex +1 more source
Twice-yearly inclisiran injections halve LDL-cholesterol levels [PDF]
, 2020 Irene Fernández-Ruíz
openalex +1 more source
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function [PDF]
, 2023 Assunta Di Costanzo +4 more
openalex +1 more source